SurgeryNCT01706640
An Open Label,Observational, Real Time Data Capturing of Usage & Outcome of Coseal
An observational study of Surgery, run by Medanta, The Medicity, India at 1 site in India.
Trial summary
This study is Open- Label, Observational, Prospective, Real-time data capturing of Usage, Outcome \& Physician satisfaction of Coseal in Cardio- Vascular-Thoracic Operative and Re- Operative procedures. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Surgery
- How many people
- 750 participants
- Where
- 1 siteIndia
- Study dates
- Dec 2012to May 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient falling under inclusion criteria can take part in to bthe study
Who may be able to join
- Patients undergoing cardiovascular and thoracic surgery who require use of Coseal as a treatment strategy.
- Patient undergoing open, Video Assisted surgery and robotic surgery to be included and analysed as subgroups
- Written informed consent obtained from the patient or legal representative for data collection post surgery in patients who had Coseal used intraoperatively (data privacy laws).
Who cannot join
- Known hypersensitivity to components of the investigational product
- Known Immune system disorders, immunodeficiency
- Concomitant use of any other anti-adhesion product
- Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days
- Unplanned re-operation in case of use for anti-adhesion
- Contraindications for use of Coseal
Trial locations and contacts
1 site in 1 country.
India1 site
Medanta, The Medicity
Gurgaon, Haryana, 122 001
Dr. Ali Z Khan, MS,FRCS,
About this study
Official title: An Open- Label,Multicentre, Observational, Prospective, Real-time Data Capturing of Usage, Outcome & Physician Satisfaction of Coseal in Cardio- Vascular- Thoracic Operative and Re- Operative Procedures
This study is Open- Label, Observational, Prospective, Real-time data capturing of Usage, Outcome \& Physician satisfaction of Coseal in Cardio- Vascular-Thoracic Operative and Re- Operative procedures.
Objective of this study is to assess current practice pattern and best practice sharing of usage of Coseal by collecting data on (1) Sealing suture lines along arterial and venous reconstruction(2) Patients undergoing cardiac surgery to prevent or reduce the incidence, severity and extent of post surgical adhesion enforcement of suture lines in lung resection procedures (3) From this data to document and generate a real life experience on the use of Coseal in cardio vascular and thoracic surgery.
Number of expected patient enrollment is 750 from 20 participating sites.
Read the detailed description
Objectives:
- Assessing current practice pattern and best practice sharing of usage of Coseal as per IFU by collecting data on oSealing suture lines along arterial and venous reconstructions oPatients undergoing cardiac surgery to prevent or reduce the incidence, severity and extent of post surgical adhesion enforcement of suture and staple lines in lung resection procedures
- From this data to document and generate a real life experience on the use of Coseal in cardio vascular and thoracic surgery
- To possibly create a guideline for usage of Sealant in routine practice in India
- To study delivery methods and clinical impact in minimally invasive surgery like VATS and robotic surgery
End points
Primary Endpoint
- Cardio vascular sealing: To report the effectiveness and safety of COSEAL in the control of anastomotic suture line and needle hole suture bleeding during vascular reconstruction by checking the incidence of immediate anastomotic sealing and the presence of persistent intra-operative and postoperative bleeding average time to achieve hemostasis for a single bleeding site after 60 s of clamping without manual compression In case of sternotomy, Hemostasis time in mns, which is operative time comprised between the removal of cardio-pulmonary bypass cannulae and the closure of the sternum. Overall postoperative bleeding in mL/m² revision for bleeding Minor complications, major complications, mortality
- Efficacy of Coseal in prevention or reduction of adhesion in re-do surgeries for patients with staged operations for congenital cardiac malformation re-operated on during the follow-up period of the registry Incidence of adhesions. location and extension of adhesion by measuring the percentage of surface affected for each of the following regions: pericardial or retrosternal, inferior or diaphragmatic region, right lateral or atrial region, region around the great vessels, pulmonary surface. Overall evaluation (dissection easy or difficult) Incidence of subjects free of adhesions. Severity (at each of these sites, the adhesions will be graded as follows: absence of adhesion; 1: filmy and avascular; 2: dense and/or vascular; and 3: cohesive)
- Air leak: incidence of immediate (at the time of closure) and prolonged post-operative air leak, Use in redo surgery for air leak.
Secondary Endpoints
- Cardiovascular (sealing and adhesion prevention):
- Total operative time
- Nature and duration of first operation
- Nature and duration of redo operation, and time for dissection from sternotomy to end of dissection for prevention of adhesions )
- Length of intensive care stay
- Length of hospital stay
- Infection rate
- Quality of wound healing
- Quality of life (SF36)
- Thoracic and Lung
- Sealing the suture/ staple line on table Use of buttressing
- Total operative time
- Drain output
- Drain duration
- Length of hospital stay
- Prolonged air leak (more than 5 days) (>5 days is the new standard for prolonged aire leak accepted in 2011 by the EU Soc of CVTS, see ref.)
- Infection rate
- In all cases,
- intra and post-operative blood loss
- FFP, Transfusion
- Reoperation for bleeding purpose
- Others
- Surgeons satisfaction
- Easiness of product handling during application (VAS)
- Conditions
- Surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardio Vascular Outcome
To report the effectiveness and safety of COSEAL in the control of anastomotic suture line and needle hole suture bleeding during vascular reconstruction by checking the incidence of immediate anastomotic sealing and the presence of persistent intra-operative and postoperative bleeding
Measured: 18 months
Secondary outcomes (2)
Cardiovascular (sealing and adhesion prevention):
To Capture total operative time,nature and duration of first operation,nature and duration of redo operation, and time for dissection from sternotomy to end of dissection for prevention of adhesions )
Measured: 18 months
Thoracic and Lung (Sealing and Adhesion prevention)
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2012 (estimated)
- Study startDec 2012
- Primary completionNov 2013 (estimated)
- Study completionMay 2014 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 750 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medanta, The Medicity, India
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Ali Zamir Khan, Medanta, The Medicity, India
- Investigators
- Dr. Ali Z Khan, MS,FRCS,FRCS, Principal investigator, Medanta, The Medicity
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01706640
- Sponsor's protocol ID
- MM/CTVS/2012/001
- Status last verified
- Oct 2012
- First submitted
- 8 Oct 2012
- Last updated
- 15 Oct 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open- Label,Multicentre, Observational, Prospective, Real-time Data Capturing of Usage, Outcome & Physician Satisfaction of Coseal in Cardio- Vascular- Thoracic Operative and Re- Operative Procedures
- ClinicalTrials.gov ID
- NCT01706640
- Acronym / sponsor ID
- MM/CTVS/2012/001
- Conditions
- Surgery
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 750 participants (estimated)
- Lead sponsor
- Medanta, The Medicity, IndiaUniversity, hospital or other
- Study start
- Dec 2012
- Primary completion
- Nov 2013 (estimated)
- Study completion
- May 2014 (estimated)
- First posted
- 15 Oct 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is Open- Label, Observational, Prospective, Real-time data capturing of Usage, Outcome \& Physician satisfaction of Coseal in Cardio- Vascular-Thoracic Operative and Re- Operative procedures.
Objective of this study is to assess current practice pattern and best practice sharing of usage of Coseal by collecting data on (1) Sealing suture lines along arterial and venous reconstruction(2) Patients undergoing cardiac surgery to prevent or reduce the incidence, severity and extent of post surgical adhesion enforcement of suture lines in lung resection procedures (3) From this data to document and generate a real life experience on the use of Coseal in cardio vascular and thoracic surgery.
Number of expected patient enrollment is 750 from 20 participating sites.
Detailed description
Objectives:
- Assessing current practice pattern and best practice sharing of usage of Coseal as per IFU by collecting data on oSealing suture lines along arterial and venous reconstructions oPatients undergoing cardiac surgery to prevent or reduce the incidence, severity and extent of post surgical adhesion enforcement of suture and staple lines in lung resection procedures
- From this data to document and generate a real life experience on the use of Coseal in cardio vascular and thoracic surgery
- To possibly create a guideline for usage of Sealant in routine practice in India
- To study delivery methods and clinical impact in minimally invasive surgery like VATS and robotic surgery
End points
Primary Endpoint
- Cardio vascular sealing: To report the effectiveness and safety of COSEAL in the control of anastomotic suture line and needle hole suture bleeding during vascular reconstruction by checking the incidence of immediate anastomotic sealing and the presence of persistent intra-operative and postoperative bleeding average time to achieve hemostasis for a single bleeding site after 60 s of clamping without manual compression In case of sternotomy, Hemostasis time in mns, which is operative time comprised between the removal of cardio-pulmonary bypass cannulae and the closure of the sternum. Overall postoperative bleeding in mL/m² revision for bleeding Minor complications, major complications, mortality
- Efficacy of Coseal in prevention or reduction of adhesion in re-do surgeries for patients with staged operations for congenital cardiac malformation re-operated on during the follow-up period of the registry Incidence of adhesions. location and extension of adhesion by measuring the percentage of surface affected for each of the following regions: pericardial or retrosternal, inferior or diaphragmatic region, right lateral or atrial region, region around the great vessels, pulmonary surface. Overall evaluation (dissection easy or difficult) Incidence of subjects free of adhesions. Severity (at each of these sites, the adhesions will be graded as follows: absence of adhesion; 1: filmy and avascular; 2: dense and/or vascular; and 3: cohesive)
- Air leak: incidence of immediate (at the time of closure) and prolonged post-operative air leak, Use in redo surgery for air leak.
Secondary Endpoints
- Cardiovascular (sealing and adhesion prevention):
- Total operative time
- Nature and duration of first operation
- Nature and duration of redo operation, and time for dissection from sternotomy to end of dissection for prevention of adhesions )
- Length of intensive care stay
- Length of hospital stay
- Infection rate
- Quality of wound healing
- Quality of life (SF36)
- Thoracic and Lung
- Sealing the suture/ staple line on table Use of buttressing
- Total operative time
- Drain output
- Drain duration
- Length of hospital stay
- Prolonged air leak (more than 5 days) (>5 days is the new standard for prolonged aire leak accepted in 2011 by the EU Soc of CVTS, see ref.)
- Infection rate
- In all cases,
- intra and post-operative blood loss
- FFP, Transfusion
- Reoperation for bleeding purpose
- Others
- Surgeons satisfaction
- Easiness of product handling during application (VAS)
Study design
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient falling under inclusion criteria can take part in to bthe study
Key inclusion criteria (3 listed)
- Patients undergoing cardiovascular and thoracic surgery who require use of Coseal as a treatment strategy.
- Patient undergoing open, Video Assisted surgery and robotic surgery to be included and analysed as subgroups
- Written informed consent obtained from the patient or legal representative for data collection post surgery in patients who had Coseal used intraoperatively (data privacy laws).
Key exclusion criteria (6 listed)
- Known hypersensitivity to components of the investigational product
- Known Immune system disorders, immunodeficiency
- Concomitant use of any other anti-adhesion product
- Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days
- Unplanned re-operation in case of use for anti-adhesion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cardio Vascular Outcome
Time frame: 18 months
To report the effectiveness and safety of COSEAL in the control of anastomotic suture line and needle hole suture bleeding during vascular reconstruction by checking the incidence of immediate anastomotic sealing and the presence of persistent intra-operative and postoperative bleeding
2 secondary outcomes
Cardiovascular (sealing and adhesion prevention):
Time frame: 18 months
Thoracic and Lung (Sealing and Adhesion prevention)
Time frame: 18 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2012.
Related trials for Surgery
RecruitingPhase 4
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
Laparoscopic Surgery, Visceral Pain, Postoperative
RecruitingPhase 1
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
Not yet recruitingObservational study
Arterial Stiffness During Negative Pressure Wound Therapy for Abdominal Wall Wounds
Postoperative Abdominal Wall Wound Complications, Surgical Wound Infection
Recruiting
Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Sacrocolpopexy (ProGYNious)
Pelvic Organ Prolapse (POP), Synthetic Mesh
Active, not recruitingPhase 2
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Ali Z Khan, MS,FRCS,FRCS principal investigator
Medanta, The Medicity
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Surgery, run by Medanta, The Medicity, India at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Oct 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Dr. Ali Z Khan, MS, FRCS, (9958001672, drkhanresearch@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardio Vascular Outcome (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2012.